Luca Benatti is Chief Executive Officer and member of the Board of TES Pharma. He has over 30 years’ experience in Pharma and Biotech. He was the CEO of EryDel since 2012, recently acquired by Quince Therapeutics. and the Co-founder and CEO of Newron Pharmaceuticals. Under his guidance, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's disease. He is an independent Board member at Newron Pharmaceuticals (NWRN), Quince (QNCX), Cas Revolution, Chairman of the Italian Angels for Biotech, Member of the Advisory Board of the Sofinnova-Telethon fund. He has authored several scientific publications and holds numerous patents. Luca is Italian citizen. Luca is a member of the R&D and the audit and risk committees. Luca is Italian citizen